Chikungunya in 2025: Comprehensive Insights into Virology, Diagnostics, Vaccines, and Antiviral Therapies

Read full text
Authors: Zeyong Zheng, Hua Ji, Zeping Shan, Jiangcheng Xu, JiaRui Li, Xueting Zhang, Jiajia Zheng, Shibo Jiang, Naru Zhang
Cited by: 3
References: 132

Abstract

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus prevalent in more than 110 countries and regions, including Africa, Asia, the Americas, and Europe. It can cause acute fever, rash, and severe joint pain, and some patients may develop chronic arthritis, which significantly impairs quality of life. CHIKV infection can occasionally be fatal, with neurologic disease a particularly severe manifestation. Following its resurgence in 2005, CHIKV has emerged as a major threat to global public health. This review summarizes diagnostic techniques, advances in vaccine development, and the latest drug interventions for CHIKV. We also present an overview of the epidemiology, structure, and invasion mechanisms of epidemic hotspots in 2024-2025 and propose evidence-based strategies for effective prevention and control of CHIKV infection.

Fields of Study & Subjects

Mosquito-borne diseases and control Viral Infections and Outbreaks Research Biological Research and Disease Studies

Publication details

Journal / source
Viruses
Publisher
MDPI AG
Volume
18
Issue
1
Pages
100–100
Publication date
12 January 2026
Language
EN